IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC trimmed its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 84.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 52,313 shares of the company's stock after selling 281,664 shares during the period. Voya Investment Management LLC owned about 0.06% of IDEAYA Biosciences worth $1,344,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Barclays PLC grew its position in shares of IDEAYA Biosciences by 188.8% in the 3rd quarter. Barclays PLC now owns 181,170 shares of the company's stock worth $5,739,000 after buying an additional 118,438 shares during the period. JPMorgan Chase & Co. raised its stake in IDEAYA Biosciences by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 79,780 shares of the company's stock worth $2,527,000 after acquiring an additional 12,029 shares during the period. SG Americas Securities LLC grew its holdings in IDEAYA Biosciences by 444.2% during the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock valued at $475,000 after buying an additional 15,089 shares in the last quarter. KBC Group NV grew its holdings in shares of IDEAYA Biosciences by 84.6% in the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock valued at $108,000 after purchasing an additional 1,923 shares in the last quarter. Finally, R Squared Ltd purchased a new position in shares of IDEAYA Biosciences in the fourth quarter valued at $35,000. 98.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Royal Bank of Canada reiterated an "outperform" rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Finally, Stephens reiterated an "overweight" rating and set a $50.00 target price on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, IDEAYA Biosciences currently has a consensus rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Stock Performance

IDYA traded down $0.81 on Friday, hitting $17.37. The company had a trading volume of 1,191,762 shares, compared to its average volume of 990,259. The stock has a fifty day moving average price of $17.74 and a 200-day moving average price of $22.59. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $44.42. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -5.26 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the firm posted ($0.53) earnings per share. Analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.